Pixium Vision SA is involved in clinical trials related to late-stage macular degeneration. Self-described assets have been acquired by Science Corporation.

Pixium Vision SA

Pixium Vision SA, a bioelectronics and brain machine interface technology company, specialized in neuromodulation application. It develops PRIMA System, a bionic vision system for patients with severe vision loss due to retinal degeneration caused by the dry atrophic form of Age-related Macular Degeneration (AMD); and to treat bilndness, which replace the normal physiological function of the eye's photoreceptor cells by electrically stimulating the nerve cells of the inner retina, which then transmit the visual information to the brain via the optic nerve. The company has collaboration agreements with Stanford University in California, Institut de la Vision, Moorfields Eye Hospital, Institute of Ocular Microsurgery, University Hospital, and UPMC. Pixium Vision SA was founded in 2011 and is based in Paris, France.

ALPI

COM:PIXIUM-VISION

Pixium Vision SA

Last Close

0.42

30/01 16:35

Market Cap

1.16M

Beta: -

Volume Today

86.01K

Avg: -

Analysis Not Available